Global AI in Synthetic Biology Market 2025 – 2034

Reports Description

As per the AI in Synthetic Biology Market conducted by the CMI Team, the global AI in Synthetic Biology Market is expected to record a CAGR of 28.63% from 2025 to 2034. In 2025, the market size is projected to reach a valuation of USD 30.76 Billion. By 2034, the valuation is anticipated to reach USD 192.95 Billion.

Overview

The rising synthetic biology market is on the increase as a result of advancements in genetic engineering, biotechnology, and AI technologies. North America dominates the market, particularly the United States, where key players and research institutions are located, with significant efforts in biotechnology research. Europe is the second-largest region for the synthetic biology market, with Germany being the largest driver of growth in this region. The Asia-Pacific region is a growing segment of the synthetic biology market. Countries like China and India have invested large sums of money in synthetic biology to address health care challenges, improve agricultural outcomes, and address environmental issues.

In terms of categories, healthcare and medicine hold the largest share of the synthetic biology market due to the growing demand for personalized medicine, gene therapies, and vaccines. Industrial biotechnology is also a large market category and is the use of synthetic biology for biofuels, biodegradable plastics, sustainable chemicals, and the sustainable production of proteins. Agricultural biotechnology is a growing segment using synthetic biology for genetically modified organisms (GMOs). One of the large benefits of using synthetic biology is for crops with enhanced qualities.

The synthetic biology market is growing, with growing investment in research and development, potential mergers and acquisitions, and the formation of strategic partnerships. The synthetic biology market is also aligned with sustainability (sustainable resources) and focuses on protecting the environment and being able to manufacture products cost-efficiently. The future will see ongoing continuous innovation in the synthetic biology market and its impact across multiple sectors and can provide sustainable and health-centred solutions.

Key Trends & Drivers                                                                                                  

The AI in Synthetic Biology Market Trends presents significant growth opportunities due to several factors:

• Technological Developments in Genetic Engineering: Recent technological developments in gene editing and synthetic biology (including CRISPR) have provided a significant uplift to the synthetic biology sector. Innovations in genetic editing enable scientists to alter genes in a more effective and more accurate way, leading to new therapeutics, biofuels, or better crops. Once we can invent and/or engineer synthetic life forms or genetic modifications, we are only limited by our imagination, and the application possibilities in diagnostics, therapeutics, agriculture, and industry are nearly limitless. As technologies become more accessible and affordable, it is anticipated that synthetic biology will penetrate new markets and stimulate further advancements in many sectors.

• Increased Demand for Personalized Medicine: The increased demand for personalized medicine is an important driver for the synthetic biology market as well. Developments in biotechnology and genomics increasingly enable the development of customized therapies that take into consideration individual genetic variations. Personalized medicine also provides better outcomes, less recovery time, and better efficiency in health care. As the demand for customized medicine solutions continues, synthetic biology applications will likely gain importance in developing more targeted therapies, such as gene therapy, biologics, banked stem cells, and other therapeutic interventions that are aimed at the genetic profile of the patient, resulting in direct growth in the market.

• Sustainability and Environmental Benefits: A key motivation for investment in synthetic biology is the increasing emphasis on sustainability, which has been identified as a concern across multiple industries through reducing environmental impact. As industries strive to overcome their carbon footprint, synthetic biology produces bio-based materials, including biodegradable plastics, biofuels, and bio-based chemicals. In addition to reducing the use of fossil fuels, the waste from these industries is reduced. Accordingly, synthetic biology aligns with the global recognition of climate change and its push toward sustainable development. As consumer preferences and expectations lean toward socially responsible consumption and environmental regulations tighten, the synthetic biology market overall, and particularly in specific sectors of interest, including industrial biotechnology and renewable energy, will continue to grow.

• Applications in Agriculture: An area in which synthetic biology is rapidly evolving is agriculture. For example, genetically modified crops with new traits such as pest resistance, increased yield, and drought resistance are being developed. This is an important goal, considering the looming population growth’s effect on meeting future food supply and scarcity challenges. Synthetic biology also provides improved fertilizers and pesticides with a smaller environmental footprint than traditional agricultural processes. Further, agricultural industries result in a food security crisis seemingly independently of the synthetic biology context. The ongoing development of solutions will contribute to agricultural sustainability challenges, and with this goal in mind, the population will clamour and lead to continued industry growth as well.

Significant Threats

The AI in Synthetic Biology Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

• Regulatory and Ethical Challenges: The regulatory challenges related to ethical and safety concerns in synthetic biology are substantial as the industry works through complexities. Regulatory frameworks for synthetic biology are still to be fully developed politically or legally in nearly every country in the world. Global companies face uncertainty due to differing and contradictory regulations, which may lead to delays in bringing new products and technologies to market. Public perceptions of biohacking, GMOs, and other potential harms from synthetic biology (e.g., ecological risk, biosecurity) can be barriers to public acceptance of synthetic biology products and may create a potential backlash of public resistance to products being developed from synthetic biology. Collectively, these challenges could threaten innovation, increase compliance costs and legal challenges, and hinder the scale of the industry.

• High Costs of R&D and Manufacturing: The escalating costs of R&D and manufacturing in synthetic biology are a significant threat to the industry, particularly for SMEs. Development of new synthetic biology products, such as genetically engineered organisms or highly sophisticated bio-based products, typically requires significant investments in R&D and capex, which may present barriers for some firms. The high costs of scaling production to an industrial scale would limit the accessibility of many markets. These frictions with R&D costs, manufacturing routes, capital requirements, and scale would affect research-intensive synthetic biology firms to adopt a lean approach to the critical processes of biological design and synthetic biology production technologies so that the pressures from the challenges may place so much financial uncertainty on the firms that they may decide not to pursue investments and proceed with marketable ventures.

Opportunities

• Expanding Need for Sustainable Solutions: As the world continues to address sustainability, synthetic biology serves as an opportunity for identifying and meeting the growing need for sustainable products. Industries including agriculture, energy, and manufacturing are more obliged to reduce their environmental footprint. Synthetic biology delivers many sustainable options for chemical-derived (e.g., petroleum) products, such as biodegradable plastics, biofuels, and bio-based chemicals. By relying on renewable biological resources as feedstocks, synthetic biology can help to break the reliance on fossil fuels, allow for reduced carbon emissions, and diminish the environmental burden from fossil fuel extraction and waste. There is a growing need for sustainable solutions stemming from consumer demand and regulations from the government to be more environmentally sustainable, which can help meet this consumer demand. This creates tremendous opportunities for companies to develop and eventually commercialize bio-based products as solutions to the environmental, social, and economic issues facing our society.

• Medical and Healthcare Improvements: Advancements in synthetic biology are providing unparalleled opportunities in the medical and healthcare sectors. Gene therapy is one of the most groundbreaking areas that synthetic biology will help revolutionize by potentially allowing for tailored treatments for genetic diseases. Technologies in synthetic biology, such as CRISPR and genome editing, are all aiming to offer the potential to stem the genetic mutation in a treatment at the DNA stage, to then be developed for treatments that can vastly improve or cure conditions that were once thought impossible to treat. Additionally, synthetic biology will be a major component of personalized medicine, as treatments now and in the future will be substantially based on patient-specific genetics.

Category Wise Insights

By Technology

• Gene Synthesis: Gene synthesis is the process that allows scientists to build custom DNA sequences in the laboratory, resulting in the ability to design novel genes for specific purposes. Gene synthesis is essential for creating organisms that are genetically engineered, for producing therapeutic proteins, and inter-relatedly broader interrelated goals, for promoting the use of biotechnology. As synthesizers have increased in speed and precision, the costs of gene synthesis are coming down, and the ability to scale synthesis is improving. This will promote biomedical innovations and provide agricultural solutions to meet the demands of consumers, driving innovation in the areas of health, agriculture, and environmental sustainability.

• Genome Editing: Genome editing most commonly refers to CRISPR, which is used to make precise changes to an organism’s genome. Genome editing is useful for providing solutions to improve agricultural productivity, generate disease-resistant crops, and produce personalized gene therapies. As genome editing techniques become more precise and refined, genome editing will proliferate across applications in the human healthcare and agriculture sectors.

• Synthetic Biology Tools: Synthetic biology tools enable the design, construction, and analysis of new biological systems. Synthetic biology tools include both software for genetic design and automated laboratory equipment and gene assembly processes. Synthetic biology tools provide improved capability to undertake genetic engineering and therefore are an important area to develop synthetic biology better suited for drug discovery and where designing, building, and testing new biologicals could work best for the industrial biotechnology space.

• Bioinformatics: Bioinformatics refers to the computational tools used to organize, store, and analyze biological data such as genome sequences and protein structures. Bioinformatics is the foundation of understanding complex biological systems and synthesizing organisms.

By Application

• Biotechnology and Medicine: At present, synthetic biology is beginning to transform drug discovery and development, diagnostics, and other forms of personalized medicine. These advances are producing new gene therapies to treat genetic disorders, along with new therapeutic proteins and vaccines through advances in synthetic biology. Advances in gene synthesis and genome editing through synthetic biology have the potential to address unmet medical needs and lead to better outcomes for patients (along with providing better patient care).

• Agricultural Biotechnology: The use of synthetic biology in agriculture is revolutionizing and transforming the agricultural system by making genetically modified crops with desirable traits like pest resistance, higher product yield, and drought-resistant crops. Synthetic biology can also produce more sustainable agricultural farming practices, like bio-pesticides and bio-fertilizers, for food security and environmental impacts.

• Industrial Biotechnology: Synthetic biology in industry is moving towards developing bio-based chemicals, fuels, and materials. Synthetic Biology and Bio-based production are reducing our reliance on fossil fuels by developing microorganisms engineered to produce valuable and important compounds. An example of the development in synthetic biology and bio-based production is in the development of biofuels, biodegradable plastics, and other green products.

• Environmental Biotechnology: Environmental biotechnology heavily utilizes synthetic biology to generate solutions for waste management, pollution remediation, and sustainable utilization of resources. Engineered microbes can remediate and degrade plastics and other pollutants, such as heavy metals, in extreme environments and heavy metals.

Impact of Recent Tariff Policies

The recent U.S. tariff policies, which include a baseline tariff of 10% and increased duties on all imports from China and Vietnam, have greatly affected synthetic biology’s practices related to artificially accelerating the evolution of organisms. The tariffs have caused delays in supply chains, caused production costs to rise, and created uncertainties that have effects on the parent’s response and prospects for the future. As a result, companies in the biotechnology space faced increases in costs that affected companies’ expense structures, particularly for small and medium-sized enterprises (SMEs) that may spend a higher proportion of revenue on tariffs on essential raw materials and components of production. This, then, may increase the price of its end products, reducing access for end users and motivation to purchase biotech-related products.

Faced with these situations, many companies are re-evaluating their supply chain strategies. Many firms are looking into reshoring initiatives to lower their risk of reliance on third-party foreign suppliers and enhance domestic production capacity. While this shift can provide benefits in robustness to the supply chain, it takes substantial investment (time and resources) to overhaul systems and processes to accommodate this action. In addition, many firms are ramping up their research and development efforts to innovate, create, and evaluate alternative materials to imported materials. Of course, creating new product solutions can come with its costs.

Report Scope

Regional Analysis

The AI in Synthetic Biology Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

• North America: Synthetic food, films, fertilizers, drugs, fuels, etc., as biobased products, is the biggest part of the synthetic biology market’s sheer economic growth area over biobased chemicals and pharmaceuticals. The amount of investment and emergence of new start-ups, particularly in the US, is evidence of the breadth and depth of the market. North America is perhaps the strongest region with regard to all aspects relating to synthetic biology, as well as the former. North America is the headquarters of several early entrants, Ginkgo Bioworks and Amyris being two retail applicators. The US government and other North American countries have become biocompatible with regard to funding biotechnology research. Above all, North America’s funding, regulation, and support of research and development have provided a speedier platform for advances in health care as well as agriculture, industrial biotechnology, etc. In addition, North America leads not only in the regulation and support of research and development but also in data and technological adoption and licensing compared to other regions. Market maturity will drive growth over geographies. The trends are leading the synthetic biology market in North America. In healthcare, e.g., gene therapy is at the forefront of developments in clinical, regulatory, and reimbursement pathways. And in sustainable bio-manufacturing, to the extent that it increases as opposed to traditional manufacturing and chemical processing systems, particularly at a local or regional scale.

• Europe: Europe has made significant strides in advanced research programs involving synthetic biology processes and materials due to a diversity of innovation drivers and public and private organisations that stimulate take-up action. The emerging European market for synthetic biology has witnessed a rapid increase in investment and engagement with regard to publicly and privately funded research and development in conjunction with high regulatory and ethical capabilities that can increase the pace of new and developed products and solutions. The emergence of different-staged external-partner organisations in the UK, Germany, and France, and their collaborative arrangements, is the source of many, if not most, overall synthetic bioproduction innovations. The funding from the European Union’s Horizon 2020 program has also contributed to the overall development of synthetic biology processes. While the market is at a diverse growth stage, the interrelatedness between each of the levels of action related to synthetic biology products and materials provides a stable path whereby the activity between academia, various types of industries, and government/regulation remains intertwined. Growth in research and collaboration across a diversity of public and private partner players is promoting continued diverse innovations with synthetic biology and biofuels, biodegradable plastics, and genetically modified crops. Europe has also supported investment and research into sustainable biomanufacturing processes to address these initiatives in order to reduce the carbon footprint as well as redirect inefficient chemical manufacturing in the region.

• Asia-Pacific: Asia-Pacific is experiencing rapid advances in synthetic biology, with China and India becoming significant contenders in the market. With a huge population, booming biotechnology sector, and government support for innovation, the Asia-Pacific region sees vast potential and demand for genetically modified crops and sustainable biomanufacturing solutions. China is making huge investments in synthetic biology research and development, and it already has a larger presence in the global biotech market. China is emerging as a focal point for developments in genome editing and gene synthesis. India has a rapidly advancing agricultural biotechnology sector and is seeing rapid growth in healthcare as well. The growth of bio-based chemicals will be a significant opportunity for the Asia-Pacific region, as will the use of synthetic biology for sustainable solutions.

• LAMEA (Latin America, Middle East, and Africa): Synthetic biology in LAMEA is still emerging, with growth potential on the horizon. For example, synthetic biology has opened up avenues for import and export with countries in Latin America, which are focused almost solely on agricultural biotechnology and biofuels. As they leverage synthetic biology for food security and increased crop yields, in combination with how synthetic biology contributes to sustainable energy, many countries are interested in the potential of synthetic biology. The Middle East region is investing in biomanufacturing and biotechnology as part of its diversification and shift away from oil-dependent economic ventures. Lastly, Africa is also beginning to develop in the area of synthetic biology, with growth especially focused on healthcare and agricultural (about food security) solutions.

Key Developments

In recent years, the AI in the Synthetic Biology Market has experienced several crucial changes as the players in the market strive to grow their geographical footprint and improve their product line and profits by using synergies.

• In October 2024, Ginkgo Bioworks launched a proprietary large language model (LLM) for protein engineering and an API for researchers and developers to use the model and the other synthetic biology AI systems. This follows a previous collaboration with Google Cloud to advance AI’s potential in synthetic biology.

• In October 2024, Amyris received a $12.3 million grant from the U.S. Administration for Strategic Preparedness and Response (ASPR) through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-C) to develop three key small-molecule drugs to address U.S. drug shortages and improve domestic pharmaceutical manufacturing capabilities.

• In February 2025, Thermo Fisher Scientific announced its acquisition of Solventum’s purification & filtration business for roughly $4.1 billion, which will enhance its biologic medication development and manufacturing capabilities with improved tools and services to speed drug development for biopharma companies.

• In August 2024, Illumina and the Broad Institute collaborated to develop new gene sequencing kits based on CRISPR technology to enable PerturbSeq screening and scale up gene sequencing volume. This partnership is expected to facilitate advances in disease research and treatment.

• In November 2024, GenScript Biotech Corporation’s natural sweet protein obtained approval to launch the product into the U.S. market after finishing its industrial-scale trial.

These important changes facilitated the companies ability to widen their portfolios, to bolster their competitiveness, and to exploit the possibilities for growth available in the AI in Synthetic Biology Market. This phenomenon is likely to persist since most companies are struggling to outperform their rivals in the market.

Leading Players

The AI in the Synthetic Biology Market is highly competitive, with a large number of product and service providers globally. Some of the key players in the market include:

• Ginkgo Bioworks
• Amyris
• Thermo Fisher Scientific
• Illumina
• GenScript
• Synthetic Genomics
• Novozymes
• LanzaTech
• Zymergen
• Twist Bioscience
• Codexis
• Cambrian Biopharma
• Moderna
• Editas Medicine
• Vertex Pharmaceuticals
• CRISPR Therapeutics
• Arbor Biotechnologies
• Synthego
• Evonik Industries
• Cargill
• Others

These companies implement a series of techniques to penetrate the market, such as innovations, mergers and acquisitions, and collaboration.

The synthetic biology market is competitive, with both big multinational firms, niche biotech firms, and research institutions being innovators in the space. Companies like Ginkgo Bioworks, Amyris, and Thermo Fisher Scientific lead product applications (in GMOs, biofuels, and bio-based chemicals). Other firms (such as Illumina and GenScript) focus on providing supporting tools and services (e.g., gene synthesis, genome editing, bioinformatics) that are vital for synthetic biology-related research.

The synthetic biology market is both traditional product and service-based, with companies offering a variety of biotechnology products such as engineered microbes, therapeutic proteins, and genetically modified crops, as well as critical services, including genetic sequencing, gene editing platforms, and synthetic biology tools. The overall competitive landscape is characterized by strong collaborations between private and public sectors and academia and partners and has a vibrant emerging ecosystem of competitors and market potential. This space is competitive, and companies must be able to innovate quickly and continue to update to meet regulatory and market demands.

The AI in Synthetic Biology Market is segmented as follows:

By Technology

• Gene Synthesis
• Genome Editing
• Synthetic Biology Tools
• Bioinformatics

By Application

• Healthcare & Medicine
• Agricultural Biotechnology
• Industrial Biotechnology
• Environmental Biotechnology

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America